ALZAMEND

Our lead product candidate (AL001) that we have licensed and have begun clinical development in humans for the treatment of Alzheimer's, bipolar disorder, MDD and PTSD. Our preclinical data for AL001 treatment showed prevention of cognitive deficits, depression and irritability in APPSWE/PS1dE9 mice, and is superior in improving associative learning, memory, and irritability, compared with lithium carbonate treatments. On September 11, 2021, a first-in-human Phase I six-month clinical trial for AL001 commenced with the first patients dosed. Topline data for AL001 was reported on December 17, 2021, and the full data set was released in March 2022. The data affirmed that dose-adjusted relative bioavailability analyses of the rate and extent of lithium absorption in plasma indicate that AL001 at 150 mg dosage is bioequivalent to the marketed 300 mg lithium carbonate product and the shapes of the lithium plasma concentration versus time curves are similar. AL001 salicylate plasma..

Also known as: Alzamend Neuro, Inc., Alzamend Neuro®, Alzamend, Inc.

Primary location: Atlanta United States